Secor Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Secor Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-33,972	Closed	-$3.16M	–	487
2017 Q3	$3.16M	Buy	33,972 +7,568	+29%	+$669K	0.3%	109
2017 Q2	$2.4M	Buy	26,404 +14,693	+125%	+$1.34M	0.22%	150
2017 Q1	$1.03M	Buy	+11,711	New	+$1.04M	0.11%	240
2016 Q2	–	Sell	-7,168	Closed	-$591K	–	583
2016 Q1	$591K	Buy	+7,168	New	+$583K	0.08%	283

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Secor Capital Advisors's BMRN Position: Q4 2017 in Review

Secor Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 33,972 shares — an estimated $3.16M sold.

Secor Capital Advisors first reported a position in BMRN in Q1 2016 and held it in 4 quarters. The position peaked at $3.16M in Q3 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

Secor Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Secor Capital Advisors sold 33,972 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $3.16M.
Secor Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 4 quarters.
Secor Capital Advisors's BioMarin Pharmaceuticals position peaked at $3.16M in Q3 2017.
438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Secor Capital Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.